

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number
WO 2004/005256 A2

(51) International Patent Classification⁷: **C07D 211/34**,
211/64, 223/04, 223/06

2, I-37135 Verona (IT). **TRANQUILLINI, Maria, Elvira**
[IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2,
I-37135 Verona (IT).

(21) International Application Number:
PCT/EP2003/007127

(74) Agent: **KONDO, Rie**; GlaxoSmithKline, CN925.1, 980
Great West road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 2 July 2003 (02.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0215393.0 3 July 2002 (03.07.2002) GB
0306454.0 20 March 2003 (20.03.2003) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALVARO, Giuseppe** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **CARDULLO, Francesca** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **DI FABIO, Romano** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **GIOVANNINI, Riccardo** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **PIGA, Elisabetta** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS



(57) Abstract: The present invention relates to cyclic amine derivatives of formula (I) (I) wherein R represents halogen, C1-4 alkyl, cyano, C1-4 alkoxy, trifluoromethyl or trifluoromethoxy; R1 represents hydrogen, halogen, C3-7 cycloalkyl, hydroxy, nitro, cyano or C1-4 alkyl optionally substituted by halogen, cyano or C1-4 alkoxy; R2 represents hydrogen or C1-4 alkyl; R3 and R4 independently represent hydrogen, cyano, C1-4 alkyl or R3 together with R4 represents C3-7 cycloalkyl; R5 represents trifluoromethyl, S(O)t C1-4 alkyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy, halogen or cyano; R6 represents hydrogen or (CH2)rR7; R7 represents hydrogen, C3-7 cycloalkyl,

NH(C1-4alkyl)OC1-4alkoxy), NH(C1-4alkyl), N(C1-4alkyl)2, OC(O)NR9R8, NR8C(O)R9 or C(O)NR9R8; R9 and R8 independently represent hydrogen, C1-4 alkyl or C3-7 cycloalkyl; m represents zero or an integer from 1 to 4; n represents 1 or 2; p is zero or an integer from 1 to 3; q is an integer from 1 to 3; r is an integer from 1 to 4; t is 0, 1 or 2; provided that when m is 0, p is 2, q, r and n represent 1, R1, R2, R3, R4, R5 and R7 are hydrogen and R is chlorine, R5 is not iodine; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.